Urgent

Cystic fibrosis — adult pulmonary exacerbation

cf-pulmonary-exacerbation · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Acute worsening in an adult with cystic fibrosis - increased cough, sputum volume/purulence, breathlessness, reduced FEV1, weight loss, fatigue. Management is aggressive airway clearance and prolonged culture-directed IV antibiotics (typically targeting Pseudomonas) within specialist CF multidisciplinary care, alongside CFTR modulators and nutritional/comorbidity support.

Red flags

  • Massive haemoptysis
  • Pneumothorax (sudden pain/breathlessness)
  • Severe hypoxaemia / respiratory failure
  • Burkholderia cepacia complex or new resistant organism isolation
  • Failure to recover FEV1 despite treatment
  • Decompensated CF-related diabetes or severe weight loss

Assessment

Differential diagnosis

  • Non-CF bronchiectasis exacerbation
  • Allergic bronchopulmonary aspergillosis (common in CF)
  • Non-tuberculous mycobacterial infection
  • Pneumothorax (increased CF risk)
  • Haemoptysis from bronchial vessels
  • CF-related diabetes decompensation contributing
  • Pulmonary embolism

Investigations

  • Spirometry - fall in FEV1 from baseline is a key objective marker
  • Sputum culture incl. Pseudomonas, Staph aureus (incl. MRSA), Burkholderia cepacia complex, and mycobacteria (AFB/NTM) with sensitivities
  • CXR (compare baseline; exclude pneumothorax/consolidation); consider CT
  • Oxygen saturation +/- ABG if severe
  • FBC, U&E, LFTs, CRP, glucose/HbA1c (CF-related diabetes), weight/BMI
  • Aspergillus serology/total IgE if ABPA suspected
  • Review chronic colonisation history to target antibiotics

Management

  • Manage within / in discussion with a specialist CF centre and MDT
  • Intensify airway clearance physiotherapy and mucoactive therapy (dornase alfa, hypertonic saline)
  • Start culture-directed antibiotics - usually TWO anti-pseudomonal agents of different classes IV for ~14 days to limit resistance
  • Add anti-staphylococcal / organism-specific cover based on the patient's known flora (e.g. MRSA, Burkholderia)
  • Optimise nutrition: high-calorie intake, pancreatic enzyme replacement, fat-soluble vitamins; manage CF-related diabetes
  • Continue CFTR modulator therapy (e.g. elexacaftor-tezacaftor-ivacaftor) where eligible - it reduces exacerbations and improves lung function
  • Treat complications: pneumothorax, massive haemoptysis (bronchial artery embolisation), ABPA
  • Monitor renal function and drug levels with aminoglycosides; reassess FEV1 response
  • Discharge planning with home IV/outpatient follow-up where appropriate

Drugs & doses

Anti-pseudomonal beta-lactam, e.g. ceftazidime 2 g IV TDS, or piperacillin-tazobactam 4.5 g IV TDS, or meropenem 2 g IV TDS - 14 days [verify local dose]
PLUS second anti-pseudomonal, e.g. tobramycin IV once daily (dose by level/weight) or ciprofloxacin - dual cover to limit resistance [verify dose/levels]
Anti-staphylococcal cover if S. aureus/MRSA colonised, e.g. flucloxacillin or vancomycin per sensitivities [verify dose]
Dornase alfa 2.5 mg nebulised once daily (mucolytic)
Nebulised hypertonic saline 7% BD (pre-treat with bronchodilator) [verify local dose]
Pancreatic enzyme replacement (e.g. pancreatin/CREON) with meals + fat-soluble vitamins (A,D,E,K)
CFTR modulator (e.g. elexacaftor-tezacaftor-ivacaftor) where genotype-eligible - continue through exacerbation [verify eligibility]

Disposition

Admit under / in close liaison with a specialist CF centre for IV antibiotics and MDT care (strict infection-control segregation). Selected patients: home/outpatient IV therapy. Lifelong specialist follow-up; transplant referral in advanced disease.

Complications & pitfalls

  • Progressive bronchiectasis and chronic respiratory failure
  • Pneumothorax, massive haemoptysis
  • Multidrug-resistant and Burkholderia infection (prognostic and transplant implications)
  • ABPA, NTM infection
  • CF-related diabetes, malnutrition, osteoporosis
  • Need for lung transplantation in end-stage disease

Exam pearls

  • CF exacerbations are usually treated with TWO anti-pseudomonal antibiotics of different classes for ~14 days to maximise efficacy and limit resistance (CF Foundation / specialist consensus).
  • Base antibiotic choice on the patient's own chronic sputum microbiology - CF patients carry individualised resistant flora.
  • CFTR modulators (e.g. elexacaftor-tezacaftor-ivacaftor) have transformed outcomes and should be continued/optimised in eligible patients.
  • Airway clearance and nutrition are as important as antibiotics - do not neglect physiotherapy, enzymes, and vitamins.
  • Burkholderia cepacia complex isolation has major prognostic and transplant implications and needs strict infection control (patient segregation).
  • Always manage via a specialist CF centre with MDT input.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.